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doi:10.1016/j.kjms.2011.10.031Abstract Positive serum antinuclear antibody (ANA) is not infrequent in chronic hepatitis C
virus (HCV)-infected patients. This prospective study evaluated the impact of ANA on the
response to and safety of peginterferon/ribavirin combination therapy for chronic hepatitis
C patients in clinical practice. We enrolled 243 consecutive patients who were treated with
a 24-week regimen of peginterferon-a plus ribavirin, with a 24-week follow-up period. ANA
titer was determined before antiviral treatment. The primary end-point was sustained virolog-
ical response (SVR), defined as HCV RNA <50 IU/mL throughout the follow-up period. Overall,
187 (77.0%) patients experienced a SVR. In the 105-patient HCV genotype non-1 group, patients
with ANA titer 1:80 had a significantly lower SVR rate than those with ANA titer <1:80 (67.7%
vs. 95.8%, respectively, pZ 0.013). In contrast, in the 138-patient HCV genotype 1 group, the
SVR rate did not differ between patients with and without ANA titer 1:80. Multivariate regres-
sive analyses showed that ANA 1:80, age and HCV RNA levels were independent factors asso-
ciated with SVR in HCV genotype non-1 patients; whereas HCV RNA levels and hepatic fibrosis
were prognostic predictors of SVR in HCV genotype 1 patients. The frequencies of adverse
events were similar between patients with and without ANA seropositivity. Peginterferon/riba-
virin combination therapy is effective and safe in ANA-positive chronic hepatitis C patients.Hepatobiliary Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital,
ng City 807, Taiwan.
du.tw, d850082@gmail.com (M.-L. Yu).
vier Taiwan LLC. All rights reserved.
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The prevalence of various immunological phenomena,
including autoimmunity and autoimmune disease, in
patients exposed to the hepatitis C virus (HCV) are
reportedly high [1,2]. Autoantibodies are commonly found
in patients with chronic hepatitis C (CHC) [3]. The preva-
lence of different non-organ-specific autoantibodies
(NOSA), including antinuclear antibodies (ANA), anti-
smooth-muscle antibodies, antimitochondrial antibodies,
anti-neutrophil-cytoplasmic antibodies, and anti-liver/
kidney microsomal antibodies, were investigated before,
during and after monotherapy with interferon-a (IFN) for
CHC [4,5]. The former analyses of the influence of NOSA on
the clearance of the HCV are controversial. Some studies
have suggested that there is no difference between
autoantibody-positive and autoantibody-negative patients
on IFN [6,7] or IFN/ribavirin combination therapy [8]. In
contrast, others have implied that there is a tendency
towards worse long-term biochemical and virological
responses in autoantibody-positive patients [9,10].
Recently, combination therapy with poly-ethylene-glycol-
IFN (PEG-IFN) and ribavirin has produced higher sustained
virological response (SVR) rates than conventional treat-
ment with IFN and ribavirin [1,11]. Combination therapy
with PEG-IFN and ribavirin has therefore become a standard
therapy for CHC but, so far, no study has investigated the
relevance of autoantibodies with regard to treatment
response in CHC patients taking PEG-IFN and ribavirin in
combination.
ANA, a marker for autoimmune liver disease and other
inflammatory conditions, has been detected in 441% of
patients with CHC infection in several studies [5,12,13]. We
found that ANA seropositivity is associated with lower HCV
RNA levels and advanced fibrosis in Taiwanese CHC patients
[14]. Our recent studies among such patients after combi-
nation therapy with IFN and ribavirin have shown a favor-
able response, suggesting that viral and host immunological
factors might predict therapeutic responses [15e19].
Patients who had ANA titer of 1:80 were frequently
excluded from standard clinical trials; thus the impact of
ANA seropositivity 1:80 on the safety and efficacy of the
treatment of CHC patients is unclear. We therefore con-
ducted a prospective study to evaluate the impact of ANA
on the response and safety to PEG-IFN/ribavirin in CHC
patients and to identify clinical, biochemical or immuno-
logical features that can predict the responses to antiviral
treatment in ANA-positive patients in clinical practice.
Materials and methods
Patients
Individuals who were eligible for the study were previously
untreated Taiwanese CHC patients, aged 20e70 years. Allpatients: (1) were seropositive for HCV antibodies (anti-
HCV) with serum HCV RNA detected by polymerase chain
reaction for at least 6 months; (2) underwent a liver biopsy
consistent with CHC within 6 months of entering the study;
and (3) displayed elevated serum alanine aminotransferase
(ALT) levels, defined as 1.5 times the upper limit of the
normal range for at least two measurements within the 6
months preceding the trial entry. Patients with hepatitis B
surface antigen (HBsAg), HIV infection, decompensated
cirrhosis, primary biliary cirrhosis, sclerosing cholangitis,
Wilson’s disease, a1-antitrypsin deficiency, a current or past
history of alcohol abuse (20 g daily), previous liver trans-
plantation or evidence of hepatocellular carcinoma were
excluded from the study. All subjects were thoroughly
screened for autoimmune diseases during detailed physical
examination and history taking; none of our patients had
received treatment for previous or present systemic auto-
immune diseases involving multiple diverse organs and
tissues (systemic lupus erythematosus, rheumatoid arthritis,
Sjo¨gren’s syndromes, etc.). The liver histology was assessed
by one pathologist who was unaware of the ANA status of the
individual biopsies and all other clinical information.
Study design
The Bureau of National Health Insurance in Taiwan is now
reimbursing HCV treatment using 24-week combination
therapy for all genotypes. Patients who enrolled were
prescribed peginterferon (PEG) a-2b (PEG-Intron, Schering-
Plough Inc., Kenilworth, NJ) at a dose of 80e100 mg/week
(1.5 mg/kg/week) subcutaneously, or PEG a-2a (PEGASYS,
Hoffmann-La Roche, Basel, Switzerland) at a dose of
180 mg/week subcutaneously, plus oral ribavirin
1000e1200 mg daily in two divided doses for 24 weeks. The
doses of ribavirin were based on body weight, with 1000 mg
for patients 75 kg and 1200 mg for patients >75 kg. All
patients were monitored for a further 24 weeks after the
treatment ended. They had biweekly outpatient visits
during the first month and monthly visits throughout the
remaining treatment and 24-week follow-up periods. At
each visit, there was a physical examination, and adverse
events were recorded. Liver function, complete blood
count and serum creatinine level were evaluated at each
visit. HCV RNA was tested every 12 weeks for 48 weeks. The
disease activity grade and stage of fibrosis were quantita-
tively scored according to the histological activity index
[20]. This study was approved by the Kaohsiung Medical
University Hospital Ethics Committee in accordance with
the Declaration of Helsinki, and informed consent was ob-
tained from all patients who enrolled.
Dose modifications
The adverse event profiles of PEG-IFN/ribavirin were graded
as mild, moderate, severe or potentially life-threatening.
Table 1 Basic demographic and virological features of 243
chronic hepatitis C patients.
Feature Value
Agea (years) 51.0  10.9
Sex
Male 153
Female 90
ASTa (IU/L) 113.4  68.7
ALTa (IU/L) 181.1  125.9
Total serum globulin (N Z 138) (mg/dl) 3.62  0.58
HCV RNA levela (log IU/mL) 5.33  0.95
HCV genotypes
1b (n, %) 107 (44.0)
2a (n, %) 85 (35.0)
2b (n, %) 13 (5.3)
Mixed (n, %) 33 (12.6)
Unclassified (n, %) 5 (2.1)
HAI (N Z 243)
Necroinflammatory scorea 5.0  2.4
Fibrosis scorea 1.6  1.1
F0e2 (n, %) 191 (75.2)
F3e4 (n, %) 52 (24.8)
SVR (n, %) 187 (77.0)
ANAþ (n, %) 100 (41.2)
Titer (n Z 100)
1:40 (n, %) 86 (86.0)
1:80 (n, %) 7 (7.0)
1:160 (n, %) 6 (6.0)
1:320 (n, %) 1 (1.0)
ASMAþ (n Z 127) (n, %) 23 (18.1)
Key: ALT Z alanine aminotransferase, ANA Z antinuclear anti-
body, ASMA Z anti-smooth muscle antibody, AST Z aspartate
aminotransferase, HAI Z histological activity index, HCV Z
hepatitis C virus, SD Z standard deviation, SVR Z sustained
virological response.
a Presented as mean  standard deviation.
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ribavirin was lowered to 600 mg/day when severe adverse
events occurred or when laboratory results showed:
 hemoglobin <9 g/dL in patients with no cardiac
disease;
 hemoglobin decrease >2 g/dL in subjects with cardiac
disease;
 neutrophils <750/mm3; or
 a platelet count <50,000/mm3.
Full doses could be resumedwhen the eventwas resolved.
If the event persisted, both drugs were discontinued.
Therapy was permanently discontinued if life-threatening
events occurred or when laboratory results showed hemo-
globin <7.5 g/dL in subjects with no cardiac disease,
hemoglobin<12 g/dL in subjects with cardiac disease after 4
weeks of dose reduction, neutrophils <500/mm3, a platelet
count <30,000/mm3 or serum creatinine >2.0 mg/dL.
Laboratory tests
Anti-HCV was detected with commercially-available third-
generation enzyme-linked immunosorbent assay kits
(enzyme-immunoassay, Abbott Laboratories, North Chi-
cago, IL). Serum HBsAg was assayed using commercially-
available kits (General Biological HBsAg radioimmunoassay,
General Biological Cooperation, Hsinchu, Taiwan). Aspar-
tate aminotransferase and ALT were measured on a multi-
channel autoanalyzer. ANA and anti-smooth muscle
antibody (SMA) were searched for using the indirect
immunofluorescence on Hep-2 cells method (Medical Bio-
logical Lab, Tokyo, Japan) with an initial dilution of 1:20,
following standard protocols [21,22]. Positive reactions
were titrated by double dilution to the end-point. Serum
reactivity at a dilution of at least 1:80 was considered
a positive result for ANA in the present study.
Serum HCV RNA before treatment, at the end of treat-
ment, and 12 and 24 weeks after therapy was determined
by standardized automated qualitative polymerase chain
reaction (Cobas Amplicor Hepatitis C Virus Test, version
2.0, Roche Diagnostics, Branchburg, NJ; detection limit,
50 IU/mL). HCV genotypes 1a, 1b, 2a, 2b and 3a were
determined by amplification of the core region using
genotype-specific primers [23]. Serum HCV RNA levels at
baseline and during treatment week 12 were measured
using the branched DNA assay (Versant HCV RNA 3.0, Bayer,
Tarrytown, NJ; quantification limit, 615 IU/mL).
Assessment of efficacy
SVR was defined as clearance of serum HCV RNA by the end-
of-treatment and throughout the follow-up period. Those
who had detectable HCV RNA either at end-of-treatment or
throughout the follow-up period were defined as non-SVR.
Statistical analyses
Frequency was compared between groups using the chi-
square test, with Yates’s correction, or with Fisher’s exact
test. Group means, presented as mean values  standarddeviation (SD),were comparedusing the student t test, or the
nonparametric Mann-Whitney test, when appropriate. Serum
HCV RNA levels were expressed as mean  SD after loga-
rithmic transformation of the original values. Stepwise
logistical regressionwasused to analyzewhich variableswere
independent factors related to positive ANA. The procedures
wereperformed using the SPSS 12.0 statistical package (SPSS,
Chicago, IL). All statistical analyses were based on two-sided
hypothesis tests with a significance level of p < 0.05.Results
From December 2002 to December 2005, 243 consecutive
patients (153 men and 90 women, aged 20e70 years; mean
age, 51.0  10.9) with a history of antiviral treatment of
>20 weeks were included in the final analysis. The baseline
characteristics of all 243 patients with CHC are shown in
Table 1. Of these, 138 patients had HCV genotype 1 (HCV-1)
ANA and HCV response 89infection: 107 (44.0%) were determined to have HCV-1b
infection and 31 were determined to have HCV-1b
combined with infection with other HCV genotypes; 105
patients had no HCV genotype-1 (HCV-non 1) infection.
One hundred (41.2%) patients had serum ANA titer
>1:40, including 14 patients with serum ANA titer >1:80,
seven with ANA titer >1:160 and one with ANA titer >1:320.
The immunofluorescence patterns of the ANA showed 90%
(90/100) speckled pattern; 7% (7/100) homogeneous
pattern; and 3% (3/100) mixed pattern in the 100 patients
with ANA titer >1:40. In the present study, serum ANA and
SMA were both available in 127 patients; 23 (18.1%, 23/127)
had serum SMA titer >1:40. Among these 127 patients, 13
patients had both serum SMA titer >1:40 and serum ANA
titer >1:40; 52 patients had only serum ANA titer >1:40;
and 10 patients had only serum SMA titer >1:40.
Overall, 187 (77.0%) of the 243 treated patients showed
SVR to treatment. The rates of SVR were comparable
between patients treated with PEG-IFN a-2a and a-2b
(81.1% vs. 74.3%, pZ 0.275); hence all of the patients were
considered to be a homogeneous group, even if they
received different PEG regimens. In a univariate analysis,
patients who failed to achieve an SVR were significantly
older (mean age, 54.0  9.9 vs. 50.1  11.1 years,
p Z 0.017) and had significantly higher mean HCV RNA
levels (5.7  0.6 log IU/mL vs. 5.2  0.9 log IU/mL, p
<0.001), higher mean necroinflammatory scores (5.5  2.2
vs. 4.8  2.4, p Z 0.035), and a higher frequency of F3e4
(33.9% vs. 17.6%, p <0.015), when compared to patients
with SVR (Table 2). Those with HCV-1 infection had signif-
icantly lower SVR rates (64.5% vs. 93.3%, p <0.001)Table 2 Factors associated with sustained virological response.
Factor Total SVR (n
Sex
Female (n, %) 90 67 (35
Male (n, %) 153 120 (6
Agea (y) 243 50.1 
ASTa (IU/L) 243 114.9
ALTa (IU/L) 243 189.5
HCV genotype
HCV-1 (n, %) 138 89 (47
HCV-non 1 (n, %) 105 98 (52
HCV RNA levelsa (log IU/mL) 243 5.2 
Necroinflammatory scorea 243 4.8 
Fibrosis scorea 243 1.5 
F0e2 (n, %) 191 154 (8
F3e4 (n, %) 52 33 (17
ANA titer
1:40 (n, %) 100 75 (40
<1:40 (n, %) 143 112 (5
1:80 (n, %) 14 10 (5.
<1:80 (n, %) 229 177 (9
Key: ALT Z alanine aminotransferase, AST Z aspartate aminotransfe
HCV-1 Z with HCV genotype 1 infection; HCV-non 1 Z without HCV
virological response.
a Presented as mean  SD.
b Using nonparametric Mann-Whitney test.compared to patients with HCV-non 1 infection. There was
no difference in the frequencies of different titers of ANA
between non-SVR and SVR patients. In multivariate anal-
yses, low-grade fibrosis, lower HCV RNA levels, HCV-non 1
infection and younger age were independent factors
related to SVR (Table 3).
Since HCV genotype is the most important factor asso-
ciated with SVR and patients with ANA titer were univer-
sally excluded from the clinical trial, we further stratified
patients by genotype to evaluate the impact of ANA titers
1:80 on the response to PEG-IFN and ribavirin. In the HCV-
non 1 group, patients with ANA <1:80 had a significantly
higher SVR rate than those with ANA 1:80 (95.8% vs.
67.7%, respectively, p Z 0.013). In contrast, the SVR rate
did not differ between patients with and without ANA
1:80 in the HCV-1 group (Table 4). Using multivariate
analyses, ANA titer 1:80, age and HCV RNA levels were
independent factors related to SVR in HCV-non 1; HCV RNA
levels and severity of fibrosis were independent factors
related to SVR in HCV-1 patients (Table 5).Safety profile
The rate of dose reduction of PEG-IFN or ribavirin and the
frequencies of adverse events are shown in Table 6; there
were no significant differences in the frequency of adverse
events between ANA-positive and -negative patients. None
of our patients experienced a flare-up of serum ALT levels
up to five times the upper limit of normal and/or five times
during treatment that required the withdrawal ofZ 187) Non-SVR (n Z 56) p
.8) 23 (41.1) 0.529
4.2) 33 (58.9)
11.1 54.0  9.9 0.017
 73.1 108.1  51.2 0.67b
 134.1 153.3  88.8 0.06b
.6) 49 (87.5) <0.0001
.4) 7 (12.5)
0.9 5.7  0.6 <0.0001
2.4 5.5  2.2 0.035b
1.1 2.0  1.2 0.004b
2.4) 37 (66.1) 0.015
.6) 19 (33.9)
.1) 25 (44.6) 0.643
9.9) 31 (55.4)
3) 4 (7.1) 0.743
4.7) 52 (92.9)
rase, HAI Z histological activity index, HCV Z hepatitis C virus;
genotype 1 infection, SD Z standard deviation, SVR Z sustained
Table 3 Stepwise logistic regression analysis of factors significantly associated with sustained virological response in 243
patients with chronic hepatitis C infection.
Comparison Odds ratio (95% CI) p
Dependent variable: SVR
Independent variable
HCV genotype HCV-1 Z 0, HCV-non 1 Z 1 9.469 (3.631e24.698) <0.001
Age per 1-yr increase 0.961 (0.926e0.997) 0.034
Fibrosis F3e4 Z 1, F0e2 Z 0 0.298 (0.118e0.755) 0.011
HCV RNA level per 1-log increase 0.427 (0.262e0.696) 0.001
Key: ANAZ antinuclear antibody, CIZ confidence interval, HCVZ hepatitis C virus, HCV-1Z with HCV genotype 1 infection, HCV-non
1 Z without HCV genotype 1 infection, SVR Z sustained virological response.
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titers (six patients with ANA titer 1:160 and one with
1:320) none suffered from a flare-up of serum ALT levels.Discussion
We herein present the first large-scale study undertaken to
prospectively evaluate the impact of ANA on the efficacy of
24-weeks of PEG-IFN/ribavirin combination therapy in
a group of Taiwanese CHC patients in clinical practice. We
have demonstrated that the presence of ANA seropositivity
did not influence the efficacy of treatment in patients with
HCV-1 infection. An ANA titer 1:80, however, adversely
affected the SVR in patients with HCV-non 1 infection. We
have shown that CHC patients with an ANA titer of up to
1:320 might be treated safely.
Although the 2002 National Institutes of Health
consensus statement concludes that HCV-1 infections
require PEG-IFN/ribavirin therapy for 48 weeks and HCV-2
or -3 for 24 weeks [24], the Bureau of National Health
Insurance in Taiwan is now reimbursing HCV treatment
using 24-week combination therapy for all genotypes. A 24-
week regimen of PEG-IFN/ribavirin can achieve an SVR rate
of 5065% for HCV-1 patients in Taiwan [25e27]. A number
of factors have been considered in terms of their potential
to predict the response to combination therapy, including
infection with HCV-1, high levels of viremia and the pres-
ence of advanced fibrosis, which have been reported to be
associated with a relatively poor response [28e30]. These
results are compatible with our present study, showing that
advanced fibrosis and higher HCV RNA level suggest poor
treatment efficacy.Table 4 Comparisons of sustained virological response associa
with and without genotype 1 hepatitis C virus infection.
HCV-1 (n Z 138)
ANA-positive
(n Z 5)
ANA-negative
(n Z 133)
SVR (n, %) 4 (80.0) 85 (63.9)
Non-SVR (n, %) 1 (20.0) 48 (36.1)
Key: ANA Z antinuclear antibody, ANA-positive Z titers 1:80, ANA-
HCV genotype 1 infection, HCV-non 1 Z without HCV genotype 1 infeAlthough treatment with PEG-IFN and ribavirin for 24
weeks could achieve a SVR rate of 8093% for HCV-non 1
patients, a number of the “easy-to-treat” patients
remained refractory to the currently recommended
regimen [1,11,17,24,31e33]. It is, thus, important to find
the potential prognostic factors associated with non-SVR in
the refractory subgroup. The current study demonstrates
that HCV-non 1 patients with ANA titer <1:80 had a signifi-
cantly higher SVR rate than those with ANA titer 1:80.
These results suggest that evaluation of ANA might be
helpful in predicting treatment response for HCV-non 1
patients. Nevertheless, because of the limited number of
cases in the subgroup of the current study, whether a rela-
tively difficult-to-treat HCV-non 1 patient subgroup can
benefit from a longer duration of treatment according to
the ANA titer needs further large-scale study.
Various factors including advancing age, genetic
predisposition, environmental agents, estrogen-androgen
balance, chronic infections and neoplasm are associated
with the presence of serum ANA [34]. The immune mech-
anism of liver damage is still unclear. Czaja and Carpenter
[35], however, identified a subset of CHC patients with an
autoimmune pattern of liver histology characterized by
plasma cell infiltrates. Yee and coworkers also observed
increased plasma cells in the liver biopsies of ANA-positive
individuals compared with ANA-negative individuals [6].
The increased plasma cells might be a marker for B-cell
polyclonal activity with a secondary clinical manifestation
of increased serum immunoglobulin with or without auto-
antibody production [6,35]. These observations indicate an
association between ANA and host immune status in the
liver. Williams and coworkers observed that the presence of
autoantibodies in HCV is associated with increased age andted with antinuclear antibody in chronic hepatitis C patients
HCV-non 1 (n Z 105)
p ANA-positive
(n Z 9)
ANA-negative
(n Z 96)
p
0.416 6 (67.7) 92 (95.8) 0.013
3 (33.3) 4 (4.2)
negative Z titers <1:80, HCV Z hepatitis C virus, HCV-1 Z with
ction, SVR Z sustained virological response.
Table 5 Stepwise logistic regression analysis of factors significantly associated with sustained virological response in patients
with and without genotype 1 hepatitis C virus infection.
Dependent variable Independent variable Comparison Odds ratio (95% CI) p
SVR for patients with HCV-1 infection
HCV RNA level per 1-log increase 0.487 (0.294e0.806) 0.005
fibrosis F3e4 Z 1, F0e2 Z 0 0.268 (0.092e0.781) 0.016
SVR for patients with HCV-non 1 infection
age per 1-yr increase 0.786 (0.630e0.981) 0.033
HCV RNA level per 1-log increase 0.014 (0.000e0.918) 0.045
ANA ANA 1:80Z 1, ANA <1:80Z 0 0.014 (0.000-0.480) 0.018
Key: ANA Z antinuclear antibody, ANA-positive Z titers 1:80, ANA-negative Z titers <1:80, HCV Z hepatitis C virus, HCV-1 Z with
HCV genotype 1 infection, HCV-non 1 Z without HCV genotype 1 infection, SVR Z sustained virological response.
Table 6 Dose reduction of peginterferon/ribavirin and adverse events during treatment in 243 patients with chronic hepatitis
C infection.
Feature Patients (n, %)a nZ243 ANA-positive nZ14 ANA-negative nZ229 p
Dose reduction
Peginterferon 40 (16.5%) 2 (14.3%) 38 (16.6%) 1.000
Ribavirin 85 (35.0%) 4 (28.6%) 81 (35.4%) 0.776
Peginterferon or
ribavirin
101 (41.6%) 5 (35.7%) 96 (41.9%) 0.783
Influenza-like symptoms
Fever 165 (67.9%) 8 (57.1%) 157 (68.6%) 0.387
Chills 50 (20.6%) 5 (35.7%) 45 (19.7%) 0.172
Myalgia 138 (56.8%) 8 (57.1%) 130 (56.8%) 1.000
Headache 174 (71.6%) 11 (78.6%) 163 (71.2%) 0.762
Asthenia 154 (63.4%) 8 (57.1%) 146 (63.8%) 0.776
Gastrointestinal symptoms
Anorexia 76 (31.3%) 5 (35.7%) 71 (31.0%) 0.769
Nausea 85 (35.0%) 5 (35.7%) 80 (34.9%) 1.000
Diarrhea 17 (7.0%) 1 (7.1%) 16 (7.0%) 1.000
Psychiatric symptoms
Anxiety/depression 104 (42.8%) 7 (50.0%) 97 (42.4%) 0.590
Insomnia 145 (59.7%) 8 (57.1%) 137 (59.8%) 1.000
Dermatological symptoms
Hair loss 131 (53.9%) 9 (64.3%) 121 (52.8%) 0.583
Skin rash 166 (68.3%) 11 (78.6%) 155 (67.7%) 0.558
Injection site
erythema
88 (36.2%) 6 (42.9%) 82 (35.8%) 0.580
Body weight loss 44 (18.1%) 4 (28.6%) 40 (17.5%) 0.290
Anemia (hemoglobin
<10 g/dL)
110 (45.2%) 8 (57.1%) 102 (44.5%) 0.414
Leucopenia
White cell count
<3000/mm3
185 (76.15%) 12 (85.7%) 173 (75.5%) 0.528
White cell count
<1500/mm3
6 (2.5%) 1 (7.1%) 5 (2.2%) 0.302
Thrombocytopenia
(<100 K/mm3)
110 (45.3%) 6 (42.9%) 104 (45.4%) 1.000
Abnormal thyroid
function tests
18 (7.4%) 0 (0.0%) 18 (7.9%) 0.608
a peginterferon/ribavirin for 24 weeks (n Z 243).
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92 M.-Y. Hsieh et al.an increase in interface hepatitis score. ANAs are associ-
ated with increasing age in both sexes [36]. The incidence
of ANAs increases with age and the host factors of aging
have also shown a strong association with fibrosis progres-
sion in HCV infection [37]. Thus, the pathogenesis and
progression of liver damage might relate to host immunity
and aging. In our previous study [14], we showed the
association between ANA and the more advanced hepatic
fibrosis, indicating that the evaluation of ANA as a marker
of liver disease activity in patients with CHC might be
important and helpful in predicting a more rapid progres-
sion of fibrosis.
The influence of NOSA on the efficacy of antiviral treat-
ment has been controversial in previous reports [6e10].
Since HCV genotype is the most important factor associated
with SVR, we stratified patients by genotype for further
evaluation of the influence of ANA on treatment efficacy.
After potential confounding factors were controlled, ANA
titer1:80was inversely associatedwith the achievement of
an SVR in HCV-non 1 patients, but not in HCV-1 patients. The
mechanism for the association between high ANA titer and
treatment response in HCV-non 1 patients remains unclear.
In our previous study of 614 CHC patients, ANA seropositivity
was associated with advanced fibrosis and older age [14],
which are poor prognostic factors associated with treatment
response. In the current study, as well as in previous studies
[19,25e27,29e31], ANAsmight be considered an indicator of
the length of HCV infection, with a higher ANA titer (as a host
factor) being considered a negative predictor of response to
combination treatment in patients with HCV-non 1. In
patients with HCV- 1, however, a stronger virology factor
would cushion the affect of ANA.
The immunomodulatory effects of IFN make it important
to consider the side effects and complications of the drug,
such as the abnormal thyroid function we found in our
previous studies [38,39]. The proportion of patients devel-
oping thyroid dysfunction in this study, however, was no
higher (14.7% vs. 18.7%) than in our previous reports. In this
study, none of our enrolled patients experienced a flare-up
of serum ALT, and none of the seven patients who had high
ANA titers (1:160) suffered from a flare-up of serum ALT
levels. The frequencies of adverse events were similar
between patients with and without ANA seropositivity.
These results suggest that the treatment of autoimmune
hepatitis-unrelated CHC patients with high ANA titers is
safe under close monitoring.
Conclusion
Our results demonstrate that PEG-IFN/ribavirin combina-
tion therapy is effective and safe in ANA-positive CHC
patients for whom the major diagnosis of probable auto-
immune hepatitis has been ruled out. High titer of ANA is
a negative prognostic factor of treatment response in HCV-
non 1 patients.
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